---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009298"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:28.526311+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Moleculin enrolls 45th subject in MIRACLE AML trial; interim data unblinding on track for mid-2026

## Summary
- 45th subject enrolled in pivotal Phase 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML.
- Interim unblinding of first 45 subjects remains on track for mid-2026; CEO calls it potentially the most important data moment.
- Early blinded data among first 30 patients showed 40% composite complete remission rate (30% CR, 10% CR with partial hematologic recovery).
- Approximately 35% of subjects had previously failed venetoclax-based therapies; many had adverse genetic markers.
- Enrollment progressing toward 90-subject Part A completion expected in Q3 2026; Phase 3 design to follow dose determination.

## SEC filing metadata
- accession: 0001437749-26-009298
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926009298/0001437749-26-009298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926009298/mbrx20260320_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009298
- JSON: https://secwatch.observer/filing/0001437749-26-009298.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.